Loading…
Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System
Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may...
Saved in:
Published in: | Nephron 2021, Vol.145 (4), p.392-403 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Request full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913 |
---|---|
cites | cdi_FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913 |
container_end_page | 403 |
container_issue | 4 |
container_start_page | 392 |
container_title | Nephron |
container_volume | 145 |
creator | Banoun, Helene |
description | Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may have evolved into a milder form. The increase in PCR-positive cases in late summer 2020 did not lead to the expected increase in hospitalizations, ICU admissions, and deaths, based on the severity of the disease in the spring. This difference in disease severity could be due to factors independent of the virus or to the evolution of the virus. This review attempts to identify the mutations that have appeared since the beginning of the pandemic and their role in the temporal evolution of the pandemic. There are a cell and humoral type cross-reactivity in a large part of the population to common cold coronaviruses (HCoVs) and SARS-CoV-2. Evolutionarily important mutations and deletions have emerged in the SARS-CoV-2 genes encoding proteins that interact with the host immune system. In addition, one of the major mutations (in viral polymerase) is logically associated with a higher frequency of mutations throughout the genome. This frequency fluctuates over time and shows a peak at the time when the epidemic was most active. The rate of mutations in proteins involved in the relationship to the immune system continues to increase after the first outbreak. The cross-reactivity on the 1 hand and the viral mutations observed on the other hand could explain the evolution of the pandemic until the summer of 2020, partly due to the evolution of the virus in relation to the host immune system. The immunization campaign began in December 2020: concerns are emerging about a possible escape of the circulating variants vaccines in early 2021. These variants could also escape immunity acquired through infection with the 2020 strains. |
doi_str_mv | 10.1159/000515417 |
format | article |
fullrecord | <record><control><sourceid>proquest_COVID</sourceid><recordid>TN_cdi_proquest_journals_2522353377</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2519798562</sourcerecordid><originalsourceid>FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913</originalsourceid><addsrcrecordid>eNptkd1r2zAUxUXpaEPXh72PYejLBvOmK1lffSiEkC6FbINk3atQHKlxa1upZKf0v69NOncrexKc-7vnSDoIvQP8BYCprxhjBiwDcYBGhFCWUpD8EI2Ac5xKYHCMTmO87TBCgSqaHaFjShVgAjBC8-nOl21T-DrxLlmOF8t04n-n5DxZ2F1hH3r1e9uYnoifk4UvbS81G5vMfGySq6pqa5ssH2Njq7fojTNltKfP5wm6vpz-mszS-c9vV5PxPM0ZI00qnFIiyxg4xmiegbRYSkGVcW5FsCOCC2mFc44RQclqzajlhAuDcxA8V0BP0MXed9uuKrvObd0EU-ptKCoTHrU3hf53UhcbfeN3WpJMSIo7g097g82rtdl4rnsNUwKMK9j1YR-fw4K_b21sdFXE3Jalqa1voyYMlFCScdKhZ6_QW9-GuvuKjuq7oVSIl_A8-BiDdcMNAOu-Uj1U2rEf_n7pQP4psAPe74E7E25sGIBh_-y_4x_Tyz2ht2tHnwDq8awE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2522353377</pqid></control><display><type>article</type><title>Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System</title><source>Coronavirus Research Database</source><creator>Banoun, Helene</creator><creatorcontrib>Banoun, Helene</creatorcontrib><description>Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may have evolved into a milder form. The increase in PCR-positive cases in late summer 2020 did not lead to the expected increase in hospitalizations, ICU admissions, and deaths, based on the severity of the disease in the spring. This difference in disease severity could be due to factors independent of the virus or to the evolution of the virus. This review attempts to identify the mutations that have appeared since the beginning of the pandemic and their role in the temporal evolution of the pandemic. There are a cell and humoral type cross-reactivity in a large part of the population to common cold coronaviruses (HCoVs) and SARS-CoV-2. Evolutionarily important mutations and deletions have emerged in the SARS-CoV-2 genes encoding proteins that interact with the host immune system. In addition, one of the major mutations (in viral polymerase) is logically associated with a higher frequency of mutations throughout the genome. This frequency fluctuates over time and shows a peak at the time when the epidemic was most active. The rate of mutations in proteins involved in the relationship to the immune system continues to increase after the first outbreak. The cross-reactivity on the 1 hand and the viral mutations observed on the other hand could explain the evolution of the pandemic until the summer of 2020, partly due to the evolution of the virus in relation to the host immune system. The immunization campaign began in December 2020: concerns are emerging about a possible escape of the circulating variants vaccines in early 2021. These variants could also escape immunity acquired through infection with the 2020 strains.</description><identifier>ISSN: 1660-8151</identifier><identifier>ISSN: 2235-3186</identifier><identifier>EISSN: 2235-3186</identifier><identifier>EISSN: 1660-2137</identifier><identifier>EISSN: 1660-2110</identifier><identifier>DOI: 10.1159/000515417</identifier><identifier>PMID: 33910211</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adaptive immunology ; COVID-19 - immunology ; COVID-19 - virology ; Emerging diseases ; Experimental Nephrology and Genetics: Review ; Experimental Nephrology and Genetics: Review Article ; Human health and pathology ; Humans ; Immune System ; Immunology ; Infectious diseases ; Innate immunity ; Life Sciences ; Microbiology and Parasitology ; Mutation ; Pandemics ; SARS-CoV-2 - genetics ; SARS-CoV-2 - immunology ; Virology</subject><ispartof>Nephron, 2021, Vol.145 (4), p.392-403</ispartof><rights>2021 S. Karger AG, Basel</rights><rights>2021 S. Karger AG, Basel.</rights><rights>2021. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.karger.com/Tap/Home/278492 Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Copyright © 2021 by S. Karger AG, Basel 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913</citedby><cites>FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2522353377?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,780,784,885,27925,38516,43895</link.rule.ids><linktorsrc>$$Uhttps://www.proquest.com/docview/2522353377?pq-origsite=primo$$EView_record_in_ProQuest$$FView_record_in_$$GProQuest</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33910211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03215691$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Banoun, Helene</creatorcontrib><title>Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System</title><title>Nephron</title><addtitle>Nephron</addtitle><description>Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may have evolved into a milder form. The increase in PCR-positive cases in late summer 2020 did not lead to the expected increase in hospitalizations, ICU admissions, and deaths, based on the severity of the disease in the spring. This difference in disease severity could be due to factors independent of the virus or to the evolution of the virus. This review attempts to identify the mutations that have appeared since the beginning of the pandemic and their role in the temporal evolution of the pandemic. There are a cell and humoral type cross-reactivity in a large part of the population to common cold coronaviruses (HCoVs) and SARS-CoV-2. Evolutionarily important mutations and deletions have emerged in the SARS-CoV-2 genes encoding proteins that interact with the host immune system. In addition, one of the major mutations (in viral polymerase) is logically associated with a higher frequency of mutations throughout the genome. This frequency fluctuates over time and shows a peak at the time when the epidemic was most active. The rate of mutations in proteins involved in the relationship to the immune system continues to increase after the first outbreak. The cross-reactivity on the 1 hand and the viral mutations observed on the other hand could explain the evolution of the pandemic until the summer of 2020, partly due to the evolution of the virus in relation to the host immune system. The immunization campaign began in December 2020: concerns are emerging about a possible escape of the circulating variants vaccines in early 2021. These variants could also escape immunity acquired through infection with the 2020 strains.</description><subject>Adaptive immunology</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - virology</subject><subject>Emerging diseases</subject><subject>Experimental Nephrology and Genetics: Review</subject><subject>Experimental Nephrology and Genetics: Review Article</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Immune System</subject><subject>Immunology</subject><subject>Infectious diseases</subject><subject>Innate immunity</subject><subject>Life Sciences</subject><subject>Microbiology and Parasitology</subject><subject>Mutation</subject><subject>Pandemics</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARS-CoV-2 - immunology</subject><subject>Virology</subject><issn>1660-8151</issn><issn>2235-3186</issn><issn>2235-3186</issn><issn>1660-2137</issn><issn>1660-2110</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><recordid>eNptkd1r2zAUxUXpaEPXh72PYejLBvOmK1lffSiEkC6FbINk3atQHKlxa1upZKf0v69NOncrexKc-7vnSDoIvQP8BYCprxhjBiwDcYBGhFCWUpD8EI2Ac5xKYHCMTmO87TBCgSqaHaFjShVgAjBC8-nOl21T-DrxLlmOF8t04n-n5DxZ2F1hH3r1e9uYnoifk4UvbS81G5vMfGySq6pqa5ssH2Njq7fojTNltKfP5wm6vpz-mszS-c9vV5PxPM0ZI00qnFIiyxg4xmiegbRYSkGVcW5FsCOCC2mFc44RQclqzajlhAuDcxA8V0BP0MXed9uuKrvObd0EU-ptKCoTHrU3hf53UhcbfeN3WpJMSIo7g097g82rtdl4rnsNUwKMK9j1YR-fw4K_b21sdFXE3Jalqa1voyYMlFCScdKhZ6_QW9-GuvuKjuq7oVSIl_A8-BiDdcMNAOu-Uj1U2rEf_n7pQP4psAPe74E7E25sGIBh_-y_4x_Tyz2ht2tHnwDq8awE</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Banoun, Helene</creator><general>S. Karger AG</general><general>Karger</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>COVID</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope></search><sort><creationdate>2021</creationdate><title>Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System</title><author>Banoun, Helene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adaptive immunology</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - virology</topic><topic>Emerging diseases</topic><topic>Experimental Nephrology and Genetics: Review</topic><topic>Experimental Nephrology and Genetics: Review Article</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Immune System</topic><topic>Immunology</topic><topic>Infectious diseases</topic><topic>Innate immunity</topic><topic>Life Sciences</topic><topic>Microbiology and Parasitology</topic><topic>Mutation</topic><topic>Pandemics</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARS-CoV-2 - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Banoun, Helene</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Coronavirus Research Database</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nephron</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Banoun, Helene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System</atitle><jtitle>Nephron</jtitle><addtitle>Nephron</addtitle><date>2021</date><risdate>2021</risdate><volume>145</volume><issue>4</issue><spage>392</spage><epage>403</epage><pages>392-403</pages><issn>1660-8151</issn><issn>2235-3186</issn><eissn>2235-3186</eissn><eissn>1660-2137</eissn><eissn>1660-2110</eissn><abstract>Since the reporting of the first cases of coronavirus in China and the publication of the first sequence of SARS-CoV-2 in December 2019, the virus has undergone numerous mutations. In Europe, the spring outbreak (March–April) was followed by a drop in the number of cases and deaths. The disease may have evolved into a milder form. The increase in PCR-positive cases in late summer 2020 did not lead to the expected increase in hospitalizations, ICU admissions, and deaths, based on the severity of the disease in the spring. This difference in disease severity could be due to factors independent of the virus or to the evolution of the virus. This review attempts to identify the mutations that have appeared since the beginning of the pandemic and their role in the temporal evolution of the pandemic. There are a cell and humoral type cross-reactivity in a large part of the population to common cold coronaviruses (HCoVs) and SARS-CoV-2. Evolutionarily important mutations and deletions have emerged in the SARS-CoV-2 genes encoding proteins that interact with the host immune system. In addition, one of the major mutations (in viral polymerase) is logically associated with a higher frequency of mutations throughout the genome. This frequency fluctuates over time and shows a peak at the time when the epidemic was most active. The rate of mutations in proteins involved in the relationship to the immune system continues to increase after the first outbreak. The cross-reactivity on the 1 hand and the viral mutations observed on the other hand could explain the evolution of the pandemic until the summer of 2020, partly due to the evolution of the virus in relation to the host immune system. The immunization campaign began in December 2020: concerns are emerging about a possible escape of the circulating variants vaccines in early 2021. These variants could also escape immunity acquired through infection with the 2020 strains.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>33910211</pmid><doi>10.1159/000515417</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | ISSN: 1660-8151 |
ispartof | Nephron, 2021, Vol.145 (4), p.392-403 |
issn | 1660-8151 2235-3186 2235-3186 1660-2137 1660-2110 |
language | eng |
recordid | cdi_proquest_journals_2522353377 |
source | Coronavirus Research Database |
subjects | Adaptive immunology COVID-19 - immunology COVID-19 - virology Emerging diseases Experimental Nephrology and Genetics: Review Experimental Nephrology and Genetics: Review Article Human health and pathology Humans Immune System Immunology Infectious diseases Innate immunity Life Sciences Microbiology and Parasitology Mutation Pandemics SARS-CoV-2 - genetics SARS-CoV-2 - immunology Virology |
title | Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T20%3A32%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_COVID&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evolution%20of%20SARS-CoV-2:%20Review%20of%20Mutations,%20Role%20of%20the%20Host%20Immune%20System&rft.jtitle=Nephron&rft.au=Banoun,%20Helene&rft.date=2021&rft.volume=145&rft.issue=4&rft.spage=392&rft.epage=403&rft.pages=392-403&rft.issn=1660-8151&rft.eissn=2235-3186&rft_id=info:doi/10.1159/000515417&rft_dat=%3Cproquest_COVID%3E2519798562%3C/proquest_COVID%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c552t-7f9974451f553c418e088739affb20f27678e7fff52732bd53e6267a0c176c913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2522353377&rft_id=info:pmid/33910211&rfr_iscdi=true |